Regulations.gov document
Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for…
Proposed Rule · FDA-2023-N-0061 · posted Mar 20, 2024
Key facts
| Document ID | FDA-2023-N-0061-0001 |
|---|---|
| Title | Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act |
| Document type | Proposed Rule |
| Subtype | Notice of Proposed Rulemaking (NPRM) |
| Agency | FDA |
| Docket | FDA-2023-N-0061 |
| Posted | Mar 20, 2024 |
| Federal Register citation | 89 FR 19776 |
| FR document number | 2024-05801 |
| CFR | 21 CFR Part 216 |
| Comment period opens | Mar 20, 2024 |
| Comments due | Jun 19, 2024 |
| Effective date | Mar 20, 2024 |
At a glance
- 10–99 Pages
- No Open for comment
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: